Vera V. Zarubina
Vera V. Zarubina has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Tatyana N. Kekeeva
Research Center for Medical Genetics named after Academician N.P. Bochkov
3 shared publications - Elena E. Yakushina
Morozov Children’s Clinical Hospital of the Moscow Healthcare
2 shared publications - Irina P. Vitkovskaya
Central Research Institute for Healthcare Organization and Informatization
2 shared publications - Mariya A. Mukhina
Morozov Children's Municipal Clinical Hospital
2 shared publications - Nataliia L. Pechatnikova
Morozov Children’s City Clinical Hospital
2 shared publications - Nina A. Polyakova
Morozov Children’s City Clinical Hospital
2 shared publications
Latest Publications
- Open Access
- 30 November 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (5) , 384-391
Combination of Schaaf - Yang Syndrome with Unspecified Hyperammonemia in a Newborn: Case Study
Backround . Combined pathology of primary genetic disease and rare secondary disorders presents the most diagnostical difficulties for neonatologist. Such are atypical signs of Schaaf - Yang syndrome in newborns. Case description . The premature baby was diagnosed in utero with fingers abnormality. Genetic disorder was suspected at birth due to multiple stigmas (shortened limbs, multiple joint contractures, finger deformity, cryptorchidism). Whereas severe respiratory, hemodynamic, convulsive and motor disorders, as well as pseudobulbar syndrome were regarded as manifestations of congenital pneumonia and perinatal injury of the central nervous system. Hyperammonemia was revealed at the 2nd month of life and it was regarded as secondary condition associated with combined hereditary and perinatal pathology. Any chromosome aberrations, hereditary aminoacidopathies, organic aciduria, mitochondrial diseases were excluded via multi-stage diagnostic search using karyotyping, tandem mass-spectrometry, determination of glycine concentration ratio in cerebrospinal fluid and blood. Whole-exome sequencing of the child’s DNA revealed pathogenic variant in the MAGEL2 gene in a heterozygous state (rs770374710) at the age of 3 months. This variant leads to frameshifting and premature protein translation. There were no pathological variants in the parents, thus, the patient had de novo mutation. Since there is no etiopathogenetic therapy for this disease, the patient received only syndromic therapy. Conclusion. This case demonstrates diagnostic challenges in comorbid genetic syndrome and perinatal pathology and unspecified hyperammonemia.
- 30 November 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (5) , 384-391
Open AccessCombination of Schaaf - Yang Syndrome with Unspecified Hyperammonemia in a Newborn: Case Study
Backround . Combined pathology of primary genetic disease and rare secondary disorders presents the most diagnostical difficulties for neonatologist. Such are atypical signs of Schaaf - Yang syndrome in newborns. Case description . The premature baby was diagnosed in utero with fingers abnormality. Genetic disorder was suspected at birth due to multiple stigmas (shortened limbs, multiple joint contractures, finger deformity, cryptorchidism). Whereas severe respiratory, hemodynamic, convulsive and motor disorders, as well as pseudobulbar syndrome were regarded as manifestations of congenital pneumonia and perinatal injury of the central nervous system. Hyperammonemia was revealed at the 2nd month of life and it was regarded as secondary condition associated with combined hereditary and perinatal pathology. Any chromosome aberrations, hereditary aminoacidopathies, organic aciduria, mitochondrial diseases were excluded via multi-stage diagnostic search using karyotyping, tandem mass-spectrometry, determination of glycine concentration ratio in cerebrospinal fluid and blood. Whole-exome sequencing of the child’s DNA revealed pathogenic variant in the MAGEL2 gene in a heterozygous state (rs770374710) at the age of 3 months. This variant leads to frameshifting and premature protein translation. There were no pathological variants in the parents, thus, the patient had de novo mutation. Since there is no etiopathogenetic therapy for this disease, the patient received only syndromic therapy. Conclusion. This case demonstrates diagnostic challenges in comorbid genetic syndrome and perinatal pathology and unspecified hyperammonemia.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 103-113
Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience
Objective. To assess the efficacy and safety of onasemnogene abeparvovec (OA) in children with spinal muscular atrophy (SMA) treated between 2021 and 2025 at a Moscow regional rare disease referral center (Morozov Children’s City Clinical Hospital). Material and methods. This study included 20 children with a confirmed diagnosis of 5q spinal muscular atrophy (SMA). Safety was evaluated in all 20 patients for up to 3.5 years following treatment, with adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Efficacy was analyzed in 16 patients at 8 to 37 months post-injection. Motor function was assessed using the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), while general motor development was evaluated using the Hammersmith Infant Neurological Examination, Section 2 (HINE-2). Key motor milestones were compared to established World Health Organization (WHO) norms. Data was analyzed by stratifying patients into two groups: those identified through expanded newborn screening (Group 1) and those diagnosed via high-risk screening (Group 2). Results. In Group 1, the mean age at treatment initiation was 1.9 (1.4—2.8) months, with a mean weight of 4.8 (3.7—6.25) kg. In Group 2, the mean age at treatment was 14.8 (5.5—47) months, with a mean weight of 9 (6—13.7 )kg. Within one week post-OA administration, most patients (19/20) experienced clinical symptoms, including hyperthermia (Group 1: 8/9; Group 2: 10/11), increased regurgitation/vomiting (Group 1: 5/9; Group 2: 6/11), and decreased appetite/refusal to feed (Group 1: 3/9; Group 2: 9/11). These symptoms were more severe in Group 2, requiring intravenous and symptomatic therapy, nasogastric tube placement, and parenteral nutrition in some cases. Grade 1—2 thrombocytopenia (CTCAE v.5) was observed one week post-OA in three patients from Group 2. Elevated hepatic transaminases were observed in 16/20 children: Group 1 — 6/9 (66%), Group 2 — 10/11 (90%). In Group 1, all children experienced Grade 1 elevations (CTCAE v.5), while in Group 2, 6 children had Grade 1 elevations (54%), 2 had Grade 2 (18%), 1 had Grade 3 (9%), and 1 had Grade 4 (>20x ULN) (9%). Asymptomatic troponin I elevations were recorded in 6 children from Group 1 and 4 from Group 2. The median duration of prednisolone administration was 13 weeks (8—24) in Group 1 and 21 weeks (12—42) in Group 2. In Group 1, the mean CHOP INTEND score increased by 11.5 at 4 months, the HINE-2 score increased by 10.5 points at 4 months and 15.5 points at 6 months from baseline; all children achieved main motor milestones according to WHO norms. In Group 2, the mean CHOP INTEND score increased by 4 at 6 months and 7.2 points at 12 months from baseline; the HINE-2 score increased by 2.3 points at 6 months and 4.7 points at 12 months from baseline; five children improved their functional status, and 6/9 children acquired new motor skills. Conclusion. This study presents the findings of a long-term assessment of the efficacy and safety profile of drug OA in pediatric patients across various age groups and functional ability levels, including individuals identified through expanded newborn screening. Younger patients exhibited a significantly lower incidence of adverse events and demonstrated superior therapeutic efficacy. The majority of older children experienced either positive progression or stabilization of their condition, outcomes that were largely contingent upon their initial functional status and the duration of the pre-treatment waiting period.
- 21 November 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (10) , 103-113
Onasemnogene abeparvovec gene replacement therapy for spinal muscular atrophy in children: a Moscow experience
Objective. To assess the efficacy and safety of onasemnogene abeparvovec (OA) in children with spinal muscular atrophy (SMA) treated between 2021 and 2025 at a Moscow regional rare disease referral center (Morozov Children’s City Clinical Hospital). Material and methods. This study included 20 children with a confirmed diagnosis of 5q spinal muscular atrophy (SMA). Safety was evaluated in all 20 patients for up to 3.5 years following treatment, with adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Efficacy was analyzed in 16 patients at 8 to 37 months post-injection. Motor function was assessed using the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), while general motor development was evaluated using the Hammersmith Infant Neurological Examination, Section 2 (HINE-2). Key motor milestones were compared to established World Health Organization (WHO) norms. Data was analyzed by stratifying patients into two groups: those identified through expanded newborn screening (Group 1) and those diagnosed via high-risk screening (Group 2). Results. In Group 1, the mean age at treatment initiation was 1.9 (1.4—2.8) months, with a mean weight of 4.8 (3.7—6.25) kg. In Group 2, the mean age at treatment was 14.8 (5.5—47) months, with a mean weight of 9 (6—13.7 )kg. Within one week post-OA administration, most patients (19/20) experienced clinical symptoms, including hyperthermia (Group 1: 8/9; Group 2: 10/11), increased regurgitation/vomiting (Group 1: 5/9; Group 2: 6/11), and decreased appetite/refusal to feed (Group 1: 3/9; Group 2: 9/11). These symptoms were more severe in Group 2, requiring intravenous and symptomatic therapy, nasogastric tube placement, and parenteral nutrition in some cases. Grade 1—2 thrombocytopenia (CTCAE v.5) was observed one week post-OA in three patients from Group 2. Elevated hepatic transaminases were observed in 16/20 children: Group 1 — 6/9 (66%), Group 2 — 10/11 (90%). In Group 1, all children experienced Grade 1 elevations (CTCAE v.5), while in Group 2, 6 children had Grade 1 elevations (54%), 2 had Grade 2 (18%), 1 had Grade 3 (9%), and 1 had Grade 4 (>20x ULN) (9%). Asymptomatic troponin I elevations were recorded in 6 children from Group 1 and 4 from Group 2. The median duration of prednisolone administration was 13 weeks (8—24) in Group 1 and 21 weeks (12—42) in Group 2. In Group 1, the mean CHOP INTEND score increased by 11.5 at 4 months, the HINE-2 score increased by 10.5 points at 4 months and 15.5 points at 6 months from baseline; all children achieved main motor milestones according to WHO norms. In Group 2, the mean CHOP INTEND score increased by 4 at 6 months and 7.2 points at 12 months from baseline; the HINE-2 score increased by 2.3 points at 6 months and 4.7 points at 12 months from baseline; five children improved their functional status, and 6/9 children acquired new motor skills. Conclusion. This study presents the findings of a long-term assessment of the efficacy and safety profile of drug OA in pediatric patients across various age groups and functional ability levels, including individuals identified through expanded newborn screening. Younger patients exhibited a significantly lower incidence of adverse events and demonstrated superior therapeutic efficacy. The majority of older children experienced either positive progression or stabilization of their condition, outcomes that were largely contingent upon their initial functional status and the duration of the pre-treatment waiting period.
- Open Access
- 29 December 2024
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 30 (6) , 604-615
Oral nutritional supplements in patients with cystic fibrosis: research results
BACKGROUND: The nutritional status of patients with cystic fibrosis significantly affects their survival and the function of all organs, particularly the lungs. Due to increased protein and energy needs, these patients often require high-calorie and high-protein oral nutritional supplements (ONS). AIM: To assess the tolerability, efficacy, and safety of the ONS containing whey protein and soy lecithin. MATERIALS AND METHODS: The data of 14 patients with mixed form of cystic fibrosis and nutritional deficiencies, aged between 6 and 16 years, were analyzed. Five patients received ONS containing whey protein and soy lecithin (Fresubin Protein®) as monotherapy (Group 1), four patients received the same therapeutic food together with emulsion of medium-chain triglycerides (Group 2), and five patients received ONS balanced in protein, fat, and carbohydrates (control group). The dynamics between percentile and Z-Scores of body mass index (BMI) at the beginning and at the end of the study period (day 180±2) were used as the main efficacy parameter of the investigated food. Body fat and lean body mass were assessed by caliperometry as additional efficacy parameters. RESULTS: All patients showed an increase in Z-Score and BMI percentile from baseline while taking ONS containing whey protein and soy lecithin both as monotherapy and in combination with medium-chain triglyceride emulsion. There were no statistically significant differences from the control group (p 0.05). However, Group 1 (100% of patients) demonstrated positive changes in muscle mass gain, as evidenced by caliperometry data, which was statistically significant (p 0.05) compared with the control group (20%). In Group 2, muscle gain was observed in 75% of the patients (p 0.05). CONCLUSION: These findings suggest that protein-enriched ONS not only increase BMI but also contribute to muscle mass gain in patients with cystic fibrosis. New therapeutic approaches are needed, such as the inclusion of high-protein ONS in the diet to prevent muscle mass loss, along with the monitoring of body composition to improve control of disease progression.
- 29 December 2024
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 30 (6) , 604-615
Open AccessOral nutritional supplements in patients with cystic fibrosis: research results
BACKGROUND: The nutritional status of patients with cystic fibrosis significantly affects their survival and the function of all organs, particularly the lungs. Due to increased protein and energy needs, these patients often require high-calorie and high-protein oral nutritional supplements (ONS). AIM: To assess the tolerability, efficacy, and safety of the ONS containing whey protein and soy lecithin. MATERIALS AND METHODS: The data of 14 patients with mixed form of cystic fibrosis and nutritional deficiencies, aged between 6 and 16 years, were analyzed. Five patients received ONS containing whey protein and soy lecithin (Fresubin Protein®) as monotherapy (Group 1), four patients received the same therapeutic food together with emulsion of medium-chain triglycerides (Group 2), and five patients received ONS balanced in protein, fat, and carbohydrates (control group). The dynamics between percentile and Z-Scores of body mass index (BMI) at the beginning and at the end of the study period (day 180±2) were used as the main efficacy parameter of the investigated food. Body fat and lean body mass were assessed by caliperometry as additional efficacy parameters. RESULTS: All patients showed an increase in Z-Score and BMI percentile from baseline while taking ONS containing whey protein and soy lecithin both as monotherapy and in combination with medium-chain triglyceride emulsion. There were no statistically significant differences from the control group (p 0.05). However, Group 1 (100% of patients) demonstrated positive changes in muscle mass gain, as evidenced by caliperometry data, which was statistically significant (p 0.05) compared with the control group (20%). In Group 2, muscle gain was observed in 75% of the patients (p 0.05). CONCLUSION: These findings suggest that protein-enriched ONS not only increase BMI but also contribute to muscle mass gain in patients with cystic fibrosis. New therapeutic approaches are needed, such as the inclusion of high-protein ONS in the diet to prevent muscle mass loss, along with the monitoring of body composition to improve control of disease progression.
- 6 March 2024
- Published by Open Systems Publications in Лечащий врач
- No. 3(27)
The use of medium-chain triglycerides in patients with cystic fibrosis
Background. Medium chain triglycerides are absorbed and metabolized faster than long-chain fatty acids, as they bypass the steps necessary for the absorption of long-chain fatty acids. So, they use in various malabsorptive disorders as a source of calories. Objectives. Retrospectively evaluate the clinical effectiveness of nutrition supplements (a fat emulsion consisting of medium chain triglycerides), used by patient with cyctic fibrosis. Materials and methods. 39 children with cyctic fibrosis aged 1-17 years were observed at Morozovskaya Children's Clinical Hospital. WHO-Anthro and WHO-Anthro Plus were used to determine their nutritional status. Results. At the beginning of the study, all patients with cyctic fibrosis had a body mass index < 25th percentile. The median percentile of body mass index was 7,8. 0% of patients had a Z-score body mass index > 0.25,6% of patients had a Z-score body mass index from 0 to –1. 51,3% of patients had a Z-score body mass index from –1 to –2.23% of patients had a Z-score body mass index < -2. At the end of the study, 28% of patients with cyctic fibrosis had a body mass index > 25th percentile. The median percentile of body mass index was 16,1. 18% of patients had a Z-score body mass index > 0.38,4% of patients had a Z-score body mass index from 0 to –1.25,6% of patients had a Z-score body mass index from –1 to –2, 18% of patients had a Z-score body mass index < –2. Conclusion. The use medium chain triglycerides could improve nutritional status and alleviate steatorrhea in patient with cyctic fibrosis.
- 6 March 2024
- Published by Open Systems Publications in Лечащий врач
- No. 3(27)
The use of medium-chain triglycerides in patients with cystic fibrosis
Background. Medium chain triglycerides are absorbed and metabolized faster than long-chain fatty acids, as they bypass the steps necessary for the absorption of long-chain fatty acids. So, they use in various malabsorptive disorders as a source of calories. Objectives. Retrospectively evaluate the clinical effectiveness of nutrition supplements (a fat emulsion consisting of medium chain triglycerides), used by patient with cyctic fibrosis. Materials and methods. 39 children with cyctic fibrosis aged 1-17 years were observed at Morozovskaya Children's Clinical Hospital. WHO-Anthro and WHO-Anthro Plus were used to determine their nutritional status. Results. At the beginning of the study, all patients with cyctic fibrosis had a body mass index < 25th percentile. The median percentile of body mass index was 7,8. 0% of patients had a Z-score body mass index > 0.25,6% of patients had a Z-score body mass index from 0 to –1. 51,3% of patients had a Z-score body mass index from –1 to –2.23% of patients had a Z-score body mass index < -2. At the end of the study, 28% of patients with cyctic fibrosis had a body mass index > 25th percentile. The median percentile of body mass index was 16,1. 18% of patients had a Z-score body mass index > 0.38,4% of patients had a Z-score body mass index from 0 to –1.25,6% of patients had a Z-score body mass index from –1 to –2, 18% of patients had a Z-score body mass index < –2. Conclusion. The use medium chain triglycerides could improve nutritional status and alleviate steatorrhea in patient with cyctic fibrosis.
- 10 December 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (6)
HOMOCYSTINURIA AS A RARE CAUSE OF PANCREATITIS IN CHILDREN
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 10 December 2019
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 98 (6)
HOMOCYSTINURIA AS A RARE CAUSE OF PANCREATITIS IN CHILDREN
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.